Literature DB >> 10436838

Surgical palliative treatment in bilio-pancreatic malignancy.

D J Gouma1, R van Geenen, T van Gulik, L T de Wit, H Obertop.   

Abstract

Most patients with bilio-pancreatic malignancy are no candidate for curative resection and will need palliative treatment. Palliation in these patients is focussed on relief symptoms such as obstructive jaundice, duodenal obstruction and pain. It has been suggested that non surgical treatment (stenting) is the optimal palliation for patients with short survival and surgical bypass for those surviving more than 6 months. Unfortunately valid criteria for estimating survival are not available except for metastases. A prognostic score chart to predict survival probabilities for 3,6 and 9 months after diagnosis has been developed. The use of this prognostic score chart may help clinicians to select optimal palliative treatment for individual patients. Surgical biliary drainage can be performed by a simple cholecystoenterostomy; a choledochoduodenostomy or a choledocho/hepaticojejunostomy with Roux-Y jejunal limb reconstruction. The present data available in the literature do not give sufficient guidance to make a well deliberated selection between the different types of bypass surgery but choledochojejunostomy is generally preferred. Gastroentero-stomy is performed routinely during the biliary bypass procedure in our institution because gastric outlet obstruction has been described between 9-21% of the patients who underwent only a surgical biliary bypass but there is still controversy. Recently it was also suggested that there is an indication to perform palliative resections. No results are available to justify resections as a debulking procedure.

Entities:  

Mesh:

Year:  1999        PMID: 10436838

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  7 in total

1.  Surgical palliation of unresectable pancreatic head cancer in elderly patients.

Authors:  Sang Il Hwang; Hyung Ook Kim; Byung Ho Son; Chang Hak Yoo; Hungdai Kim; Jun Ho Shin
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

2.  Usefulness of an inflammation-based prognostic score (mGPS) for predicting survival in patients with unresectable malignant biliary obstruction.

Authors:  Yoshimi Iwasaki; Mitsuru Ishizuka; Masato Kato; Junji Kita; Mitsugi Shimoda; Keiichi Kubota
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

3.  Single-stage intraoperative transhepatic biliary stenting in patients with unresectable hepatobiliary pancreatic tumors.

Authors:  Yoshimi Iwasaki; Keiichi Kubota; Junji Kita; Masato Katoh; Mitsugi Shimoda; Tokihiko Sawada; Yukihiro Iso
Journal:  Surg Endosc       Date:  2012-07-18       Impact factor: 4.584

4.  Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.

Authors:  Edwina N Scott; Giuseppe Garcea; Helena Doucas; Will P Steward; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2009-03       Impact factor: 3.647

5.  The need for a prophylactic gastrojejunostomy for unresectable periampullary cancer: a prospective randomized multicenter trial with special focus on assessment of quality of life.

Authors:  N Tjarda Van Heek; Steve M M De Castro; Casper H van Eijck; Rutger C I van Geenen; Eric J Hesselink; Paul J Breslau; T C Khe Tran; Geert Kazemier; Mechteld R M Visser; Olivier R C Busch; Hugo Obertop; Dirk J Gouma
Journal:  Ann Surg       Date:  2003-12       Impact factor: 12.969

6.  Biliary bypass surgery - Analysis of indications & outcome of different procedures.

Authors:  K Altaf Hussain Talpur; Arshad Mahmood Malik; Amir Iqbal Memon; Jawed Naeem Qureshi; Ahmed Khan Sangrasi; Abdul Aziz Laghari
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

7.  Hepaticocholecystoduodenostomy compared with Roux-en-y choledochojejunostomy for decompression of the biliary tract.

Authors:  Omar Shah; Parveen Shah; Showkat Zargar
Journal:  Ann Saudi Med       Date:  2009 Sep-Oct       Impact factor: 1.526

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.